Q4 2024 Earnings Call Transcript January 29, 2025 Stifel Financial Corp. beats earnings expectations. Reported EPS is $2.23, ...

Stifel Nicolaus analyst Matthew Smith, CFA maintained a Buy rating on Altria Group (MO – Research Report) today and set a price target of ...

Stifel lowered the firm’s price target on Danaher (DHR) to $260 from $265 and keeps a Hold rating on the shares. Danaher ...

Stifel analyst David Grossman raised the firm’s price target on IBM (IBM) to $271 from $246 and keeps a Buy rating on the ...

Stifel lowered the firm’s price target on Intel (INTC) to $21 from $25 and keeps a Hold rating on the shares. Q4 results were above management guidance and consensus estimates, but Q1 guidance came in ...

While total segment revenue declined 6.6% year-over-year due to weak truckload (TL) demand and lower rates, gross margins ...

Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy.

The firm’s CEO cited a “very competitive” recruiting market in 2024, but forecasts a better 2025 as longer-term efforts pay ...

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

The natural beauty of West Virginia will be celebrated both musically and visually in the Wheeling Symphony Orchestra’s upcoming performance, “Nature. Beauty.” Set for 2 p.m., Feb. 8, at the Capitol ...

Shares of Stifel Financial were moving higher after it reported fourth-quarter adjusted earnings that beat Wall Street ...